AMP PD data platform

The research record

This is the project's file for this landmark, as written and checked. Sources are listed at the end; anything not yet confirmed is marked "Not yet verified".

Who

The Accelerating Medicines Partnership Parkinson's Disease program (AMP PD), managed by the Foundation for the National Institutes of Health. Partners: NIH (NINDS), the US Food and Drug Administration, the Michael J. Fox Foundation (landmark 77) and five companies: Celgene, GlaxoSmithKline, Pfizer, Sanofi and Verily (NIH release and MJFF). Genetic resource paper: H. Iwaki and colleagues.

What happened

• Launch. NIH announced the partnership on 30 January 2018. The private partners would invest $12 million over five years through the Foundation for the NIH (including $2 million of in-kind software and services from Verily), and NINDS would match it with another $12 million, pending availability of funds. The release said the first analyses would combine data from more than 3,000 Parkinson's cases and 1,700 controls from NINDS- and MJFF-funded studies, including PPMI.
• Portal. The AMP PD Knowledge Portal went public on 22 November 2019. It combined data from PPMI (landmark 24), the NINDS biomarker programme and BioFIND (landmark 135) and the Harvard Biomarkers Study. Researchers apply once and use the whole set.
• Genetic resource. Version 1 (Mov Disord 2021) held whole-genome sequences of 3,941 participants from four cohorts: 2,005 with ordinary Parkinson's, 963 healthy controls, 64 prodromal, 62 with symptoms but no dopamine deficit, and 705 carriers of GBA or LRRK2 variants (304 affected). Sequencing was jointly called with the TOPMed Freeze 9 pipeline. The authors found no excess of known pathogenic variants in ordinary Parkinson's, but a higher polygenic risk score.
• Funder report (source sweep, Oct 2026). ASAP reports that AMP PD added a postmortem brain cohort (100 people, 5 regions), plasma and CSF proteomics (621 people) and the Target Explorer tool in 2023, and in 2024 widened to AMP PD Related Disorders (nine cohorts plus GP2 and PPMI data) to help tell Parkinson's from MSA, DLB and PSP.

Why it moved us toward a cure

Each cohort alone is small for genetics. Harmonising them removes months of data-cleaning for every team and lets small labs test hypotheses on genomes, RNA and long clinical follow-up together. It also complements the global genetics effort in landmark 78.

Outcome

Advanced; it is in routine use (for example, a 2025 analysis of progression in 3,001 cases). It is a resource, not a result: it has not itself identified a drug target.

Sources

• Iwaki et al., Mov Disord 2021, DOI 10.1002/mds.28549, PMID 33960523
• Michael J. Fox Foundation, AMP PD portal launch
• NIH launch news release, 30 Jan 2018 (read through an Internet Archive copy; the live page blocks automated reading)
• Lewis et al., Parkinsonism Relat Disord 2025, DOI 10.1016/j.parkreldis.2024.107186
• ASAP 2023 Year in Review · ASAP 2024 Year in Review
• Not yet verified: whether the $24 million total was fully paid out (the release says NINDS funds were "pending availability"); current data size. No correction or retraction found for Iwaki et al.